Biodexa Pharmaceuticals Files Form 6-K
Ticker: BDRX · Form: 6-K · Filed: Aug 30, 2024 · CIK: 1643918
| Field | Detail |
|---|---|
| Company | Biodexa Pharmaceuticals PLC (BDRX) |
| Form Type | 6-K |
| Filed Date | Aug 30, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer, company-update
Related Tickers: BDRX
TL;DR
Biodexa Pharma (BDRX) filed a routine 6-K, nothing major to see here.
AI Summary
Biodexa Pharmaceuticals PLC, formerly Midatech Pharma Plc, filed a Form 6-K on August 30, 2024. The company, based in Cardiff, United Kingdom, operates in the Pharmaceutical Preparations industry. This filing is a report of a foreign private issuer.
Why It Matters
This filing indicates ongoing reporting requirements for Biodexa Pharmaceuticals as a foreign private issuer, which is standard for companies listed on US exchanges.
Risk Assessment
Risk Level: low — This filing is a standard regulatory report for a foreign private issuer and does not contain new material financial or operational information.
Key Players & Entities
- Biodexa Pharmaceuticals Plc (company) — Registrant
- Midatech Pharma Plc (company) — Former company name
- August 30, 2024 (date) — Filing date
- Cardiff, United Kingdom (location) — Company headquarters
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers that is required to be filed with the SEC to provide information that the issuer makes or is required to make public pursuant to the laws of its home country or that it furnishes or is required to furnish to its security holders.
When was Biodexa Pharmaceuticals PLC previously known by another name?
Biodexa Pharmaceuticals PLC was formerly known as Midatech Pharma Plc, with a date of name change on June 2, 2015.
What is Biodexa Pharmaceuticals PLC's Standard Industrial Classification (SIC) code?
Biodexa Pharmaceuticals PLC's SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Where is Biodexa Pharmaceuticals PLC's principal executive office located?
Biodexa Pharmaceuticals PLC's principal executive offices are located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom.
Does Biodexa Pharmaceuticals PLC file annual reports under Form 20-F or Form 40-F?
Biodexa Pharmaceuticals PLC indicates that it files annual reports under cover of Form 20-F.
Filing Stats: 286 words · 1 min read · ~1 pages · Grade level 17.7 · Accepted 2024-08-30 16:38:07
Filing Documents
- z8292496k.htm (6-K) — 11KB
- ex99_1.htm (EX-99.1) — 11KB
- 0001214659-24-015793.txt ( ) — 23KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨ The information included in this report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File Number 333-209365) and Form F-3 (File Number 333 - 267932) of the Company (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SUBMITTED HEREWITH Attached to the Registrant’s Form 6-K filing for the month of June 2023 is: Exhibit No. Description 99.1 Press release dated August 30, 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Biodexa Pharmaceuticals PLC Date: August 30, 2024 By: /s/ Stephen Stamp Stephen Stamp Chief Executive Officer and Chief Financial Officer